Found 1551 of ec50 data for polymerid = 308,429,4809,50004316,50004317,50004660,50006396 TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.5nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 (isolate BRU/L...)
Glaxosmithkline
US Patent
Glaxosmithkline
US Patent
Affinity DataEC50: 0.5nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.5nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 (isolate BRU/L...)
Glaxosmithkline
US Patent
Glaxosmithkline
US Patent
Affinity DataEC50: 0.600nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.600nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 (isolate BRU/L...)
Glaxosmithkline
US Patent
Glaxosmithkline
US Patent
Affinity DataEC50: 0.700nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.710nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.800nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.800nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.800nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 (isolate BRU/L...)
Glaxosmithkline
US Patent
Glaxosmithkline
US Patent
Affinity DataEC50: 0.800nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.850nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.900nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.900nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.910nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 0.980nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 (isolate BRU/L...)
Glaxosmithkline
US Patent
Glaxosmithkline
US Patent
Affinity DataEC50: 1nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 (isolate BRU/L...)
Glaxosmithkline
US Patent
Glaxosmithkline
US Patent
Affinity DataEC50: 1nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 (isolate BRU/L...)
Glaxosmithkline
US Patent
Glaxosmithkline
US Patent
Affinity DataEC50: 1nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 (isolate BRU/L...)
Glaxosmithkline
US Patent
Glaxosmithkline
US Patent
Affinity DataEC50: 1nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 (isolate BRU/L...)
Glaxosmithkline
US Patent
Glaxosmithkline
US Patent
Affinity DataEC50: 1nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 (isolate BRU/L...)
Glaxosmithkline
US Patent
Glaxosmithkline
US Patent
Affinity DataEC50: 1nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 (isolate BRU/L...)
Glaxosmithkline
US Patent
Glaxosmithkline
US Patent
Affinity DataEC50: 1nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 (isolate BRU/L...)
Glaxosmithkline
US Patent
Glaxosmithkline
US Patent
Affinity DataEC50: 1nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 (isolate BRU/L...)
Glaxosmithkline
US Patent
Glaxosmithkline
US Patent
Affinity DataEC50: 1nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 (isolate BRU/L...)
Glaxosmithkline
US Patent
Glaxosmithkline
US Patent
Affinity DataEC50: 1nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.10nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.10nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.10nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.10nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.10nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.10nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 (isolate BRU/L...)
Glaxosmithkline
US Patent
Glaxosmithkline
US Patent
Affinity DataEC50: 1.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.20nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.20nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.20nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.20nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.20nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.20nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.20nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.30nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.30nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.30nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.30nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.30nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.30nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.30nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1 group M subtyp...)
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataEC50: 1.30nMAssay Description:To quantify the amount of protein binding to human serum, compounds were serially diluted (1:3) in DMSO and acoustically transferred onto 384-well as...More data for this Ligand-Target Pair
